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1Abbreviations
TDDS transdermal drug delivery system
FD fluorescein isothiocyanate-dextran
FL-Na fluorescein sodium
LDH lactate dehydrogenase
i.p. intraperitoneal
i.c. intracutaneous
s.c. subcutaneous
i.m. intramuscular
i.v. intravenous
AUC area under the curve
F bioavailability
PBS phosphate buffered saline
P permeability coefficient
Q cumulative permeated amount
EP electroporation
MN microneedle
2Abstract
The usefulness of intracutaneous (i.c.) injection using new type of 33 gauge
(G)-needles for systemic delivery of high molecular compounds was evaluated to
develop the novel microneedle (MN) system for delivering macromolecules into skin.
Fluorescein isothiocyanate (FITC)-dextran (FD-4; average molecular weight: 4.3
kDa) was selected as a model high molecule compound. The upper dorsal skin of
hairless rat was used as an injection site. First, intravenous (i.v.) injection of Evans
blue and i.c. injection of FD-4 were performed to investigate the safety of 33
G-needles. Then, the absorption rate and bioavailability of FD-4 were measured and
compared after i.c., subcutaneous (s.c.) and intramuscular (i.m.) injections using the
33 G-needles, while a low molecular compound, fluorescein sodium (FL-Na; 378 Da)
was used for comparison.
The 33 G-needles could provide less invasive injection and more constant
plasma level of FD-4 than conventional 27 G-needles. The i.c. injection using 33
G-needles showed higher bioavailability of FD-4 compared to s.c. and i.m. injection;
on the other hand, the i.m. injection showed the highest bioavailability for FL. Thus,
the i.c. injection with 33 G-needles was a promising way to increase the absorption
rate and bioavailability of macromolecular drugs without severe damage to skin.
Next, a minimally invasive system was developed for the delivery of
macromolecular drugs to the deep skin tissues, so called in-skin electroporation
(IN-SKIN EP), using a microneedle (MN)-electrodes array. MNs were arranged to
puncture the skin barrier, the stratum corneum, and were used as electrodes for EP so
that a high electric field could be applied to skin tissues to promote viable skin
delivery. In vitro skin permeation experiments showed that the IN-SKIN EP had a
much higher skin penetration-enhancing effect for FD-4 than MN alone or ON-SKIN
EP (conventional EP treatment), and that higher permeation was achieved by applying
3a higher voltage and longer pulse width of EP. In addition, no marked skin irritation
was observed by the IN-SKIN EP, which was determined by the lactate
dehydrogenase (LDH) leaching test. These results suggest that IN-SKIN EP can be
more effectively utilized as a potential skin delivery system of macromolecular drugs
than MN alone and conventional ON-SKIN EP.
Finally, the MN-electrode array for IN-SKIN EP was optimized to obtain
suitable skin delivery of high molecular drugs. The MN electrodes were arranged
alternately (5 anodes and 4 cathodes) or one electrode center/eight surrounding
opposite electrodes (1 cathode and 8 anodes or 1 anode and 8 cathodes). The effects
of these three devices were compared on the permeation of FD-4 through hairless rat
skin. The skin surface was observed after IN-SKIN EP application by a scanning
electron microscope to visualize the difference between the anode and cathode sites of
skin. In addition, skin irritation after IN-SKIN EP was evaluated by measuring the
skin redness and cutaneous blood flow. The obtained results suggested the better
usefulness of the IN-SKIN EP for effectively delivering FD-4 through the skin
without more severe skin irritation than conventional ON-SKIN EP. Furthermore,
the optimization of the device led to better use of the IN-SKIN EP.
4Introduction
Oral administration and intravenous injections are of two major conventional
ways to therapeutic delivery of drugs. However, the former has the hepatic first-pass
effect, and the latter shows markedly high plasma concentration of drugs [1, 2].
Transdermal drug delivery system (TDDS) has been paid more and more attention to
overcome these problems, especially for the macromolecules such as bioactive
peptides, proteins, oligonucleotides and vaccines [3-7]. However, the uppermost
layer of skin, stratum corneum, limits these dosage methods only to lipophilic and low
molecular drugs (less than 500 Da) [8] with high therapeutic potency.
Biopharmaceuticals as explained above, such as bioactive peptides, proteins,
oligonucleotides and vaccines, are rapidly growing segment in pharmaceutical
therapies [3-7]. They are currently administered via parenteral routes generally due
to high molecular weight, but they sometimes cause certain problems such as
accidental needle sticks or pain resulting in reduced patient compliance [9]. Thus,
high skin-penetration ability is necessary for developing biopharmaceutical-entrapped
TDDSs as well as low molecular drug-entrapped TDDSs.
In order to overcome the high barrier function in the stratum corneum for
delivering these macromolecular drugs through skin, several penetration-enhancing
physical means have already been evaluated in addition to chemical enhancers to
promote their skin permeation. Iontophoresis [10], electroporation (EP) [11],
phonophoresis (sonophoresis) [12] and microneedles (MN) [13] are of examples.
These physical means usually show higher activities or greater usefulness than
chemical enhancers like low molecular alcohols and aliphatic esters [14]. Among
these physical means, MN array can be utilized as an effective TDDS due to its
advantage of providing a high-performance means to deliver therapeutic drugs
through the skin barrier without causing marked skin damage [13, 15-18]. MN
5arrays can be made of polymers, metal, silicone rubber, polysaccharides and so on,
and create new pores in the stratum corneum barrier to enlarge the permeation
pathways of several drugs [19-26]; however, such new pathways do not always result
in marked skin permeation of macromolecular drugs. Combination of the MN array
with iontophoresis (MN-IP) was used to increase water flow, because electroosmosis
took place through the skin from the anode to cathode in the iontophoresis system
[27]. Electroosmosis may be used like a pump syringe for conventional injection
(injection system consisting of a needle and pump syringe). Another physical means,
EP technology, widely used for introducing DNA and RNA into cells, biological
tissues and bacteria [28, 29], is also an attracting skin-penetration enhancing method
[11, 30]. EP involves the creation of tiny and transient aqueous pathways (pores) in
the transcellular lipid region in the stratum corneum barrier by applying a high
voltage pulse for a very short period [31]. EP application with a high-voltage
electric pulse for a short period (millisecond order) results in the enhanced permeation
of high molecular compounds (molecular weight of several hundreds to kilodaltons)
through the skin [32-39].
For both MN and EP, in spite of their different mechanisms, enhancement of the
skin permeability of drugs is a result of the creation of new permeation pathways in
the stratum corneum; however, the pathways do not always persist, so that the skin
barrier function is recovered immediately after the pathways close up. TEWL
(transepidermal water loss), an index of skin permeability of drugs [40], increases
after the application of MN or EP and then decreases with time, which explains the
recovery of skin barrier function. To prolong the duration of new pathway (pore)
openings, longer microneedles were investigated [40] and electrolytes, such as
calcium salt, were applied during EP application [41] for MN and EP studies.
6On the other hand, the amount and rate of macromolecule, absorbed from the
skin tissues to systemic circulation, have not been clarified yet when using MN and
EP technologies. Even when the macromolecules were delivered into the skin
tissues, their bioavailability may be not as small molecular drugs.
In Chapter 1 of this study, a model drug, fluorescein isothiocyanate
(FITC)-dextran (FD-4; average molecular weight: 4.3 kDa), was intracutaneously,
subcutaneously and intramuscularly injected by 33G-needles, and the amount and rate
of FD-4 systemically absorbed following the intracutaneous (i.c.), subcutaneous (s.c.)
and intramuscular (i.m.) injections by 33G-needles were evaluated to demonstrate the
feasibility of transdermal delivery of macromolecules. In Chapter 2, the synergic
action of MN and EP was considered to further increase the skin permeation and
bioavailability of FD-4 to achieve a longer duration of pore opening for higher skin
permeation of the macromolecule. Then, the newly combination of MN and EP,
so-called in-skin electroporation (IN-SKIN EP), was developed to combine the
advantages of MN and EP. New MN arrays were designed and combined with EP to
enhance the permeability of hydrophilic FD-4 through the stratum corneum. The
influence of this EP system on the distribution of drugs in skin was also studied.
Besides, in Chapter 3, the respective contribution of the cathode and the anode
position was studied to the skin permeability of the drug. Then, the specific
arrangement of MN as electrodes was discussed in detail. The in vivo assessment of
this EP system was also conducted.
7Chapter 1
Usefulness of intracutaneous injection by 33 gauge-needles for systemic delivery
of high molecular compounds
1.1. Introduction
Intracutaneous (i.c.) injection is always utilized for monitoring the abnormal
response of drugs [42] or immunization [43-45], as the skin is an important immune
organ. It is also applied in anesthesiology study [46, 47]. Transdermal drug
delivery system (TDDS) has been paid great attention aiming for avoidance of
gastrointestinal side effect and hepatic first-pass effects as well as an increase in
patient compliance. Besides the conventional chemical and physical approaches to
increase skin permeation of drugs [48, 49], i.c. injection itself can be used to provide
the higher bioavailability of therapeutic quantities by evading the barrier function in
the stratum corneum. The i.c. injection using MN or needle-free injection has
already been studied as a new promising method to transdermally deliver therapeutic
drugs [50-53].
Since abundant blood capillaries are existed in the dermis, however, such blood
capillaries may be damaged by needle intervention into skin. Big needles from a
gauge (G) size of 23 to 27 G are mainly used for the subcutaneous (s.c.) and
intramuscular (i.m.) injection in patients. Reduction of gauge size of needle and
change from s.c. or i.m. to i.c. injection are expected to reduce skin damage by
injection. At the same time, injection pain may be reduced by using small needles.
On the other hand, diffusion rate of drugs through the skin tissues is affected by their
molecular weights [52]. Generally, macromolecules diffuse across tissues very
slowly [54, 55]. Thus, additional study on the drug distribution and absorption in
skin must be necessary especially for designing TDDS containing macromolecules.
8In the present study, a very small needle, newly developed 33 G-needle
(NANOPASS® 33, Terumo Corp., Tokyo, Japan), was used. FD-4 was selected as a
model drug, whereas fluorescein sodium (FL-Na; 378 Da) was chosen for comparison.
The bioavailability (F) and peak drug concentration (Cmax) in plasma of FD-4 and FL
were obtained after i.c. injection using 33 G-needles and compared with those after s.c.
and i.m. injection as well as using conventional 27 G-needles. Since the histological
structure can affect the drug absorption rate from site of injection [56-60], obtained
pharmacokinetics results were evaluated from a histological viewpoint.
1.2. Materials and methods
1.2.1. Materials
FD-4 and FL-Na were purchased from Sigma Aldrich (St. Louis, MO, U.S.A.).
Other chemicals and reagents were of analytical grade and used without further
purification.
1.2.2. Injection needles
Two sizes of injection needles, 27 G-needles (outside diameter, 0.4 mm) and 33
G-needles (outside diameter, 0.2 mm) for i.c. injection, were purchased from Terumo
Corporation (Tokyo, Japan) (Fig. 1).
Fig. 1. Photograph (a) and illustration (b) of 33 G (i) and 27 G (ii) injection needles.
91.2.3. Experimental animals
Male hairless rats (WBM/ILA-Ht, 7–9 weeks old) of approximately 280-300 g
were supplied either by the Life Science Research Center, Josai University (Sakado,
Saitama, Japan) or Ishikawa Experimental Animal Laboratory (Fukaya, Saitama,
Japan). They were kept at room temperature (25 ± 2°C) with a 12 h light–dark cycle
(07:00–19:00 h). The rats were anesthetized with urethane (1.0 g/kg, i.p.) and the
hair on their abdomen was shaved. Their body temperature was maintained at 36.5 ±
0.5 °C throughout the experiments with a piece of electric carpet (Panasonic Corp.,
Osaka, Japan). All animal experiments were authorized by the ethics committee of
Josai University (Sakado, Saitama, Japan) and conducted in according to principles of
the guidelines for animal experiments at Josai University.
1.2.4. Intravenous injection (i.v.) of Evans blue with different needles
Evans blue (1.0 mg/mL, 0.2mL) was injected into the jugular vein of rats, and
150 mM NaCl (40 µL) was intracutaneously injected with a 27 and 33 G-needles in
different sites of the upper dorsal skin. Then the appearance of injection sites was
compared to evaluate the change in the cutaneous blood vessels.
1.2.5. I.c. injection of FD-4 with different needles
FD-4 (1.0 mg/mL, 40 µL) was intracutaneously loaded with a 27 or 33 G-needles
into the abdomen of anesthetized rats. After injection, blood samples were
periodically collected from the jugular vein and centrifuged (18,800×g, 5 min, 4 °C)
to obtain plasma. The samples were frozen and stored at −20 °C until analysis.
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1.2.6. I.v. injection of FD-4/FL-Na
FD-4 or FL-Na (1.0 mg/mL, 40 µL) was injected with 27 G-needles into the
jugular vein of rats, and blood samples were collected from the contralateral jugular
vein at predetermined times. The preparation of blood samples was the same as in
1.2.5.
1.2.7. I.c., s.c. and i.m. injection of FD-4/FL-Na with 33 G needles
FD-4 or FL-Na (1.0 mg/mL, 40 µL) was loaded by i.c., s.c. and i.m. injections
with a 33 G-needles into the abdomen site of anesthetized rats. In the i.c. and s.c.
injections, the drug solution was loaded at the approximately same position in skin
without fixing the depth from the skin surface. In the i.m. injection, Evans blue was
firstly injected to confirm the site of drug delivery and the site of injection was
dissected and observed until reproducible results were obtained. The preparation of
blood samples was the same as in 1.2.5.
1.2.8. Assay
Both of FD-4 and FL in plasma samples were measured at an excitation
wavelength of 495 nm and an emission wavelength of 515 nm using a
spectrophotofluorometer (RF-5300 PC, Shimadzu, Kyoto, Japan).
1.2.9. Pharmacokinetic analysis
The systemic absorption rate and bioavailability of FD-4 and FL were
determined according to the FDA guideline [61]. Partial bioavailability from zero to
Tmax (F0-Tmax) was used as an index of absorption rate, and bioavailability in 8 h (F0-8 h)
was determined for an index of whole absorption amount. Cmax was also evaluated
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as an index of absorption rate and retard absorption.
1.2.10. Statistical analysis
Statistical analysis was performed using Student’s t-test and analysis of variance
(ANOVA). Probability less than 0.05 was considered to be significant.
1.3. Results and discussion
1.3.1. Appearance of injection site
First, i.c. injection of 150 mM NaCl was done using 27 G- or 33 G-needles in
rats. Then Evans blue was intravenously injected. When the skin tissue is
damaged by needles, Evans blue is leached from the systemic circulation into the skin
tissues [62]. The 33 G-needle caused less damage than the 27 G-needle, clearly
evaluated as shown in Fig. 2.
1.3.2. Systemic disposition of FD-4 after i.c. injection using different needles
Figure 3 shows the time course of plasma concentration of FD-4 after i.c.
injection with 27 G- and 33 G-needles into the abdomen of rats. The 27 G-needle
injection showed a higher maximum plasma concentration (0.398 ± 0.015 μg/mL) at
60 min, and lower value (0.025 ± 0.005 μg/mL) at 480 min than 33 G-needle injection
Fig. 2. Influence of i.c. injection using 27 G-needle (a) and 33 G-needle (b) on the
leaching of Evans blue from the cutaneous capillaries.
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Figure 9 shows that F0-Tmax (38.3 ± 1.0%), F0-8 h (92.1 ± 4.9%) and Cmax (1.24 ±
0.09 μg/mL) of FL after i.m. injection were higher than those after i.c. (F0-Tmax: 17.3 ±
1.1%; F0-8 h: 50.9 ± 8.6%; Cmax: 0.37 ± 0.05 μg/mL) or s.c. (F0-Tmax: 13.4 ± 0.4%; F0-8
h: 43.0 ± 7.5%; Cmax: 0.32 ± 0.02 μg/mL) injection (P<0.01), the rank order of
absorption amount was i.m. injection > i.c. injection > s.c. injection.
Fig. 8. Time course of plasma concentration of FL after i.c./s.c./i.m. injection with
33 G-needle in the abdomen of rats. Symbols: □ i.c., ◆ s.c., ▲ i.m.
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1.4. Discussion
Blood capillaries abundantly distribute in the skin, subcutis and muscle, but
capillary density and blood flow are different in these different sites [63]. When the
drug molecule is absorbed from these local tissues into the circulation after injection,
the absorption process can be considered to be two steps: (1) the drug molecules enter
blood capillaries from the topical tissues, where the absorption rate (entering rate) is
limited by the capillary density and intercapillary connections; and (2) the drug
molecules are transferred to the systemic circulation system from the local blood
capillaries, where the absorption rate is limited by blood flow of capillaries.
Based on the hypothesis as above, the capillary wall acts the rate-limiting barrier
after injection of a macromolecule, FD-4. More capillaries are found in the subcutis
than in the skin and muscle [63]. Intercapillary connections and spatial structure of
capillaries are considered as the other impact factors for drug absorption. The
capillaries distribute as a serried reticulation, and the capillaries present the typical
spatial arrangement in the subcutis and skin. On the other hand, the capillaries are
straightened in the longitudinal axis of the muscle fibers. Furthermore, rare
intercapillary connection and slight capillary tortuosity are found. Thus, the
absorption rate from the subcutis is estimated to be the highest among those from skin,
subcutis and muscle, and drugs in the muscle are estimated to be absorbed most
slowly. The present results, however, indicated that the i.c. injection showed the
highest absorption amount and rate of a high molecular compound, not in the s.c.
injection. It might be attributable to poorer elasticity of skin tissue and stratum
corneum, and the increase in the inner pressure of the skin tissues, which could
accelerate the drug diffusing into dermis, subcutaneous tissue and muscle. Thus, the
rank order in the absorption amount and rate of FD-4 was i.c. > s.c. > i.m. injection.
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FL was distributed rapidly into capillaries, because the capillary wall is not a big
barrier for the FL permeation. The absorption rate of FL into the circulation system
was rather limited by the blood flow of local capillary. The blood flow velocity of
these tissues is found to be in the order of muscle > skin > subcutis [63], which
corresponds to the presently observed results after injection of FL-Na.
1.5. Chapter conclusion
The present analysis as above indicated that the new type of 33 G-needles could
provide less invasive injection and more steady plasma drug level. I.c. injection
showed a higher absorption than s.c. and i.m. injection for a macromolecule, FD-4.
The i.c. injection was a promising way to increase the safety and bioavailability of
macromolecular drugs with low skin irritation. Furthermore, it was also confirmed
that the skin could be an effective application site for macromolecular drugs. Thus,
the delivery of macromolecular drug from skin, such as microneedle system, is clearly
beneficial and feasible.
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Chapter 2
Transdermal drug delivery by in-skin electroporation with microneedle array
2.1. Introduction
Several physical means have been evaluated in addition to chemical enhancers to
overcome the formidable barrier of the stratum corneum and promote the skin
permeation of drugs. According to the advantage of MN and EP, an electrically
active MN array was produced as a device for the present IN-SKIN EP. Each MN
could serve as a microelectrode for EP, which forms an electric field inside the skin
barrier. After the IN-SKIN EP application, drugs are administered to the skin
surface to be delivered into the deeper skin tissues. This system is different from
conventional EP (ON-SKIN EP), where electrodes are applied just on the skin surface.
IN-SKIN EP may facilitate the delivery of high molecular and hydrophilic
compounds to deep skin tissues. Furthermore, it affects only a shallow region of
skin, not a deep skin tissue by the MN-electrode array; thus, IN-SKIN EP probably
increases skin permeability but with low skin irritation.
In this chapter, skin punctures made by MN were observed by a scanning
electron microscopy (SEM) and a confocal laser scanning microscopy (CLSM). The
effects of IN-SKIN EP were investigated on the intradermal distribution and skin
permeation of FD-4 by in vitro skin permeation experiments. In addition, a lactate
dehydrogenase (LDH) leakage assay was carried out to evaluate skin damage after the
IN-SKIN EP pretreatment.
2.2. Materials and methods
2.2.1. Chemicals and animals
The chemicals and animals used in this experiment were the same as described in
the previous chapter. The hairless rats were anesthetized by peritoneal injection of
sodium pentobarbital (50 mg/kg) and hair on the abdomen was carefully shaved using
an electric clipper. Abdominal full-thickness skin was excised and adhering fat and
connective tissues were carefully eliminated with a ring-ended forceps. The excised
skin was confirmed to have no damage, and was immediately used for the experiment.
All animal experiments were authorized by the ethics committee of Josai University
(Sakado, Saitama, Japan) and conducted in according to principles of the guidelines
for animal experiments at Josai University.
2.2.2. Application of IN-SKIN EP using an MN-electrode array
The MN-electrode array for IN-SKIN EP application, shown in Fig. 10, was
prepared by modification of our previous method [27]. It was assembled using 9
acupuncture needles (Haruhari, 1.5 mm; Taiho Medical Products Co., Ltd., Hiroshima,
Fig. 10
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icrophotograph of obtuse needle tip for ON-SKIN EP.
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Japan), a silicone sheet (15 × 15 ×0.8 mm; Togawa Rubber Co., Ltd., Tokushima,
Japan), polyvinyl chloride tape (thickness: 0.2 mm, safety extra low voltage: ~600 V)
and a silver sheet (thickness: 0.1 mm), as shown in Fig. 10a. Positive and negative
electrodes were set with 4.0-mm spacing arranged alternately, as shown in Fig. 10b.
Each needle was 400 μm long with a 28° angle beveled tip, and the base diameter of
the needle was approximately 200 μm, as shown in Fig. 10c. Figure 10d shows a
SEM image of one MN tip. In order to compare the effect of IN-SKIN EP with
conventional ON-SKIN EP, the needle tips of the MN array were filed and struck with
a file and hammer to make them obtuse, as shown in Fig. 10e. This obtuse tip needle
array was used to apply EP at various points on the skin surface for ON-SKIN EP
(where the MN electrodes were applied on skin), which was a control experiment to
research the IN-SKIN EP.
The excised skin was manually punctured using the MN-electrode array with
vertical pressure of 3.53 N/cm2 for 10 sec for IN-SKIN EP, whereas for ON-SKIN EP,
the pressure was set at 0.10 N/cm2 to ensure that the needle tip did not puncture the
skin. This operation was performed on a balance to measure and control the
pressure accurately. A pulse generator (ECM 830 Electro Cell Manipulator; BTX,
San Diego, CA, USA) was used to provide the square wave of EP (1 pulse/s), at
50–200 V voltage and a pulse width of 10–100 ms.
2.2.3. In vitro skin permeation experiments
The skin permeation experiment of FD-4 was performed after pretreatment of
excised hairless rat skin with IN-SKIN EP, ON-SKIN EP or MN alone. The treated
skin was mounted on vertical Franz-type diffusion cells (available diffusion area: 1.77
cm2; volume of receiver cell: 6.0 mL) immediately after the treatment, with the
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stratum corneum side facing the donor compartment and the dermal side facing the
receiver compartment. The test FD-4 solution (1.0 mg/mL, 1.0 mL) was added to
the donor compartment, whereas phosphate-buffered saline (PBS, pH7.4, 6.0 mL)
filled the receiver compartment. The receiver solution was stirred by a magnetic bar
to ensure adequate mixing to maintain the sink condition, and was kept at 32 °C with
a water jacket.
The solution was sampled at 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0 and 8.0 h after
starting the permeation experiment, and the equal volume of fresh PBS was
immediately added to keep the volume constant. Intact full-thickness skin (no
pretreatment) was also investigated for comparison.
FD-4 concentration in the samples was determined using a
fluorospectrophotometer (RF 5300 PC; Shimadzu, Kyoto, Japan) at an excitation
wavelength of 495 nm and fluorescent emission wavelength of 515 nm [64]. The
calculated values for the cumulative amount of FD-4 that permeated the skin (µg/cm2)
were plotted versus time.
2.2.4. Scanning electron micrographic observation
Scanning electron microscopy (SEM, S-3000N; Hitachi High-Technologise
Corp., Tokyo, Japan) was used to observe the skin surface treated by IN-SKIN EP.
A skin specimen was mounted on an aluminum stub using double-sided adhesive tape
and covered with gold using an ion sputter (E-1010; Hitachi High-Technologise Corp.,
Tokyo, Japan), with the stratum corneum facing up. The samples were observed at
15 kV accelerating voltage and an approximately 20 mm working distance under a 30
Pa vacuum for skin samples.
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2.2.5. Confocal microscopic observation of drug distribution
Confocal laser scanning was also performed for the excised hairless rat
abdominal skin. After the skin permeation experiment, the skin was taken from the
diffusion cell and placed in a glass-bottomed dish (Iwaki; Asahi Glass Corp.,
Funabashi, Chiba, Japan), with the stratum corneum facing down, and FD-4
distribution in the skin was observed using a confocal laser scanning microscope
(CLSM, Fluoview FV1000; Olympus Corp., Tokyo, Japan). Fluorescence from the
sample was excited by a 473 nm Hg laser [65]. Images were collected using
FluoView software (ver. 1.5; Olympus Corp.).
2.2.6. Confocal microscopic observation (Vivascope) of puncture
The interior of the skin was observed using an in vivo confocal laser scanning
microscope (Vivascope1500, wavelength: 830 nm; Rochester, NY, USA) to measure
the actual depth of pores made by MN alone or IN-SKIN EP. This instrument can
be used to non-invasively observe the interior of tissues. Tissue morphology up to a
depth of 350 µm can be observed optically, with high sensitivity and specificity,
correlating with histological sectioning [66, 67]. The punctured areas of excised
abdominal skin of hairless rats were observed immediately after puncture with MN
alone or IN-SKIN EP.
2.2.7. Measurement of lactate dehydrogenase (LDH) leakage from skin in vivo
Hairless rats were anesthetized by i.p. injection of urethane (1.0 mg/kg), and hair
on the abdomen was carefully removed using an electric clipper. A glass cell cap
was attached using adhesive (Aronalpha®; Toagosei Co. Ltd., Tokyo, Japan) after
pretreatment with IN-SKIN EP. Earle’s balanced salt solution (EBSS, 2.0 mL) was
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then added to the glass cell cap. Whole solution was periodically collected from the
glass cell cap, and the same volume of blank EBSS was added to keep the volume
constant. LDH leached from the stratum corneum side was determined by an assay
kit (Lactate Dehydrogenase Cytotoxicity Assay Kit; Cayman Chemical Co. Ltd., MI,
U.S.A.). Non-pretreated intact skin and stripped skin were also investigated for
comparison. The stripped skin was made by stripping the stratum corneum 20 times
with tape. All experiments were carried out in vivo.
2.2.8. Statistical analysis
Statistical analysis was performed using the unpaired Student’s t-test.
Significant difference was accepted at 0.05. ANOVA was also applied in this study
[68].
2.3. Results and discussion
2.3.1. Effect of IN-SKIN EP pretreatment on the skin permeation of FD-4
Figure 11 shows the time course of the cumulative amount of FD-4 that
permeated through skin pretreated with MN, ON-SKIN EP (200 V, 10 ms, 10 pulses)
or IN-SKIN EP (200 V, 10 ms, 10 pulses). The control experiment (no
pretreatment) is also shown and was performed to establish a technique with
reproducible results. Significant differences were found in the permeation profiles
between control and pretreatment groups. Little FD-4 (0.03 µg/cm2) was permeated
through intact skin over 8 h, whereas MN and ON-SKIN EP pretreatment enhanced
the FD-4 permeability approximately 7-fold (0.20 µg/cm2) and 20-fold (0.61 µg/cm2),
respectively. Furthermore, the IN-SKIN EP showed 140-fold (4.17 µg/cm2)
permeability compared with the control permeation, suggesting a great synergistic
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effect of MN and EP on the skin permeation of FD-4.
These results, together with correlative results by conventional EP [69, 70],
indicate that the IN-SKIN EP resulted in higher drug permeability with a lower
voltage or shorter pulse width of EP. In addition, a higher skin
penetration-enhancing effect could be obtained with IN-SKIN EP than with the
previous MN-IP treatment [27], even though the permeation experiment for in vitro
MN-IP treatment continued for 15 h.
Figure 12 shows scanning electron micrographs of intact skin (a) and skin
pretreated with MN (b), ON-SKIN EP (200 V, 10 ms, 10 pulses) (c) and IN-SKIN EP
(200 V, 10 ms, 10 pulses) (d). The surface of skin pretreated with IN-SKIN EP was
observed to assess the effect of IN-SKIN EP to produce a transport channel across the
primary barrier, the stratum corneum, against drug entry to viable tissues. The
Fig. 11. Time course of the cumulative amount of FD-4 that permeated through
intact skin, skin treated with MN alone, skin treated with ON-SKIN EP and skin
treated with IN-SKIN EP. Symbols: ◇, no pretreatment (intact skin); ☐, MN
alone;△, ON-SKIN EP (200 V, 10 ms, 10 pulses); ●, IN-SKIN EP (200 V, 10 ms,
10 pulses). Each data point represents the mean ± S.E. of four or five experiments.
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diameter of the newly produced transport channels was measured horizontally and
vertically, and their average size was used as an index of channel size. The average
diameter of the channel produced by MN alone was 77 μm (Fig. 3b), and that by
ON-SKIN EP was 168 μm (Fig. 3c), but no distinct channel was produced by
ON-SKIN EP. The average diameter of the channel with IN-SKIN EP pretreatment
was 166 μm (Fig. 3d). IN-SKIN EP produced the largest and deepest pore channels
in skin, among the methods in the present study, and these channels would be new
effective permeation pathways for chemical compounds, even macromolecules.
Intradermal distribution of FD-4 after the IN-SKIN EP pretreatment was also
investigated using a CLSM. Figure 13 shows CLSM images of skin sections. It is
shown from the present in vitro skin permeation experiments that the cumulative
amount of FD-4 permeated was very limited through intact skin (Fig. 11).
Correspondingly, in Fig. 13a, the average depth of fluorescent part was 20-30 μm, so
Fig. 12. SEM microphotograph of pores on the skin surface after pretreatment. a)
Intact skin, b) MN alone, c) ON-SKIN EP (200 V, 10 ms, 10 pulses), d) IN-SKIN EP
(200 V, 10 ms, 10 pulses).
it can be considered that FD-4 was distributed only on the skin and in the stratum
corneum but not permeating to the deep part of skin. In the skin pretreated with MN
(Fig. 13b), the arrow shows puncture site by MN, where the fluorescence front was
about 60 μm depth. In the ON-SKIN EP treatment (EP condition: 200 V, 10 ms, 10
pulses) (Fig. 13c), the fluorescence was distributed into deeper tissues than intact skin
or MN pretreatment. The thickness of green fluorescence in Fig. 13a-c was well
correlated to the extent of skin permeation of FD-4 as shown in Fig. 11. Although
only a little difference was found among the picture in Fig. 13a-c, much deeper green
trails could be clearly observed through the transport channel in skin pretreated with
IN-SKIN EP (EP condition: 200 V, 10 ms, 10 pulses) (Fig. 13d). FD-4 was
Fig. 13. CL
skin. a) Inta
IN-SKIN EPSM images of FD-4 distribution after 8 h permeating intact and pretreated
ct skin, b) MN only, c) ON-SKIN EP (200 V, 10 ms, 10 pulses), d)27
(200 V, 10 ms, 10 pulses).
effectively delivered to the deep part of skin in the IN-SKIN EP.
The pore channel under the skin surface produced by MN alone and IN-SKIN EP
was observed by an in vivo confocal laser scanning microscope. A series of pictures
was taken from the surface to the deep part of the skin to analyze the depth of pores
made by MN alone or IN-SKIN EP. Figure 14a–c shows skin pores (arrow) of 0.0,
10.0, and 65 μm depth, respectively, with MN alone. No pore was found in the
depth of 65 μm (dotted line arrow). Although the MN electrode was 400 µm long
(Fig. 10c), pore depth was less than 1/6 the full length of the MN, probably due to
skin elasticity. Hairless rat skin consists of three layers: stratum corneum
(approximately 0–10 µm), viable epidermis (approximately 60–90 μm) and dermis (>
90 μm) [71]. Thus, MN tips reached the viable epidermis and bypassed the stratumFig. 14. In vivo confocal laser scanning microscopy images in the puncture direction
of the pore punctured by MN alone (a–c) and IN-SKIN EP (d-f). Depth: a) 0.0 µm,28
b) 10.0 µm, c) 65 µm, d) 0.0 µm, e) 50 µm, f) 80 µm.
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corneum. The holes punctured by MN therefore act as a permeation pathway for
high molecular compounds.
The pores made by IN-SKIN EP were also observed. Figure 14d–f shows a
similar set of images for IN-SKIN EP pretreatment to Fig. 5a–c for MN alone. EP
conditions were 200 V, 10 ms and 10 pulses. Compared to Fig. 14a–c, the pores
made by IN-SKIN EP were much larger and deeper. Limited by the quality of the
images, data were collected until a depth of 80 µm (Fig. 14f). The pore could still be
observed in the recorded depth. These data show a coincidence in depth with Fig.
13b and d. In addition, the zone of the puncture periphery, which was a circular
region of approximately 100-μm diameter, was dark in the images. This could be
considered a type of change in skin tissues, such as localized transport regions (LTR),
as well as the Joule heat effect. Although evidence of the creation of these LTRs is
still indirect in the present study, this zone is also considered as the effect of EP and
acts as an important part of drug permeation [72-75].
2.3.2. Effect of voltage and pulse width in the IN-SKIN EP treatment
Figure 15 shows the effect of the application voltage and pulse width of EP on
the cumulative amounts of FD-4 that permeated through skin pretreated by IN-SKIN
EP (over 8 h). Voltage, pulse width and the number of pulses are the three most
important parameters of the EP effect on the skin permeation [76]. In this study, the
effective application period of IN-SKIN EP was fixed to 10 s, and the square wave
pulse was applied at 1 pulse/s, so the number of pulses became 10. When the
voltage condition was 0, 50, 100 or 150 V under a pulse width of 10 ms, the
cumulative amount of FD-4 permeated through skin over 8 h was 0.20 ± 0.05, 0.23 ±
0.03, 0.64 ± 0.19 or 1.35 ± 0.91 µg/cm2, respectively. When the pulse width was
fixed to 50 ms and the voltage condition was 50, 100 or 150 V, the cumulative
amount over 8 h was 0.33 ± 0.03, 0.81 ± 0.13 or 1.96 ± 0.64 µg/cm2, respectively.
Based on these data, the cumulative amount over 8 h increased with the increase in
applied voltage with convex downward. When the voltage was increased to 200 V,
the cumulative amount increased steeply. When the voltage condition was 50 or 100
V at a pulse width of 100 ms, the cumulative amount over 8 h was 0.68 ± 0.18 or 3.00
± 0.12 µg/cm2, respectively. Increasing the pulse width to 100 ms is therefore an
effective way to achieve a high cumulative permeation drug amount, even at a lower
voltage. Although either the voltage or pulse width could markedly contribute to
FD-4 permeability through excised hairless rat skin, 200 V and 10 ms pulse width
showed the highest FD-4 permeation among the conditions evaluated in this study.
No data are shown for severe IN-SKIN EP conditions, such as high voltage (> 200 V)
or long pulse width (> 100 ms), since the sink condition could not be maintained in
the receiver solution over 8 h due to the extremely high skin permeation of FD-4.
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2.3.3. Influence of IN-SKIN EP on lactate dehydrogenase (LDH) leaching from skin
EP application was found to increase tissue temperature due to Joule heating [77].
It was considered from the present SEM images that a certain level of scorching was
found in pores punctured by IN-SKIN EP. Cutaneous cells may be damaged when
the skin is punctured by IN-SKIN EP. In order to estimate the irritation caused by
IN-SKIN EP, LDH leaching from the skin was determined. The LDH leaching was
used to assess skin viability [64, 78] in order to evaluate the safety of different
physical enhancing methods. Two strong EP conditions (200 V, 10 ms, 10 pulses
and 100 V, 100 ms, 10 pulses) were evaluated. Stripped skin was also evaluated for
comparison. Figure 16 shows the cumulative amount of LDH leached from the skin
surface over 1, 4 and 8 h after different pretreatments. The cumulative amount of
LDH leached from stripped skin was 6.6 times that from intact skin over 8 h. In
Fig. 16. Effect of different pretreatments on LDH leaching from the skin surface.
Each point represents the mean ± S.E. of three or four experiments. (*: < 0.05; **:
< 0.01) Intact skin, IN-SKIN EP (200 V, 10 ms, 10 pulses), IN-SKIN
EP (100 V, 100 ms, 10 pulses) and Stripped skin.
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contrast, no significant difference was found between intact skin and either of the
pretreatment conditions; therefore, it can be concluded that the IN-SKIN EP could
create a novel permeation route to enhance the drug penetration with little damage to
skin cells.
2.4. Chapter conclusion
It is important to surmount the stratum corneum barrier to increase permeability
to deliver macromolecules through skin. A novel IN-SKIN EP was developed to
address this challenge in this research. It was concluded from the present results of
the in vitro permeation experiment of FD-4 that treatment with MN or ON-SKIN EP
alone increased the permeation of FD-4 through excised hairless rat skin, and
IN-SKIN EP further increased skin permeation, which was due to a great synergistic
effect of MN and ON-SKIN EP. In particular, higher permeation was achieved
when applying higher voltage and longer pulse width of EP. FD-4 was concentrated
in the EP application site in this system. In the present study, the low irritation of
IN-SKIN EP could be concluded from the LDH experiment.
In conclusion, IN-SKIN EP can effectively deliver high molecular and
hydrophilic drugs. Not only drug solutions but also the topical formulations, such as
gel, ointment or a patch can be applied after pretreatment with IN-SKIN EP, and could
be more convenient for clinical application.
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Chapter 3
Development and evaluation of the microneedle-electrode array
3.1. Introduction
The combined use of two or three physical means has been found to further
increase the skin permeation of drugs [79-84]. The IN-SKIN EP, a new combination
of MN and EP, was further evaluated to further increase the skin permeation of
macromolecules, and the MN electrodes were arranged alternately (5 anodes and 4
cathodes) in the previous chapter. The application voltage of EP was considered to
be a major determining factor for the enhancing effect [31, 85], and anode and
cathode positions and the electric field strength in the stratum corneum were also
shown to be important determinants for the EP effect [86, 87]. Furthermore, the
electric field strength produced in the stratum corneum was closely related to the
permeation amount and skin concentration of drugs [86].
Considering the distribution of the electric field on the skin, electrodes in the MN
devices were set in a center-surrounding arrangement (1 cathode and 8 anodes or 1
anode and 8 cathodes). The electric field formed inside the skin barrier can be
altered by changing the MN electrode position. At the same time, the effect of
ON-SKIN EP was evaluated in addition to IN-SKIN EP using MN devices. The
IN-SKIN EP increased the skin permeability of FD-4 more than ON-SKIN EP
without severe skin damage.
In this chapter, the effects of ON-SKIN EP and IN-SKIN EP with different
devices were investigated on the in vitro skin permeation of FD-4. In addition,
changes in skin morphology were observed by a SEM after the ON-SKIN EP and
IN-SKIN EP applications. The changes in skin redness and cutaneous blood flow
were also investigated and used as for skin irritation.
3.2. Materials and methods
3.2.1. Chemicals and animals
The chemicals and animals used in this experiment were the same as described in
Chapter 1. The preparation of excised skin was the same as described in Chapter 2.
All animal experiments were authorized by the ethics committee of Josai University
(Sakado, Saitama, Japan) and conducted in according to principles of the guidelines
for animal experiments at Josai University.
3.2.2. Configurations of MN-electrode array
The MN-electrode array for IN-SKIN EP was prepared by modifying the method
in the previous chapter. It was assembled using 9 acupuncture needles (Haruhari,
1.5 mm; Taiho Medical Products Co., Ltd., Hiroshima, Japan), a silicone sheet (15 ×
15 ×0.8 mm; Togawa Rubber Co., Ltd., Tokushima, Japan), polyvinyl chloride tape
(thickness: 0.2 mm, safety extra low voltage: ~600 V) and silver sheet (thickness: 0.1
mm). The microneedle electrodes were arranged in the following three ways: i)
anodes and cathodes were arranged alternately (device A, Fig. 17a), ii) a cathode was
F
Mig. 17. Schematic representation of three kinds of MN-electrodes array patches.
Ns are arranged as a 3-by-3 array in any device. a) 5-anodes and 4-cathodes, b)34
8-anode and 1-cathode, c) 1-anode and 8- cathode.
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set in the center and 8 anodes were set around the cathodes (device B, Fig. 17b) and
iii) an anode was set in the center and cathodes were set around the anode (device C,
Fig. 17c). These MNs were arranged in a 3-by-3 array in all the devices, and were
set with 4.0-mm spacing. Each needle was 400 μm long with a 28° angle beveled tip,
and the base diameter of the needle was approximately 200 μm. In order to compare
the effect of IN-SKIN EP with conventional ON-SKIN EP, the obtuse tip needle array
was made in the same way as shown in previous chapter to apply EP at various points
on the skin surface for the ON-SKIN EP.
3.2.3. Applications of IN-SKIN EP and ON-SKIN EP with MN-electrode array
The applications of IN-SKIN EP and ON-SKIN EP were the same as described
in Chapter 2.
3.2.4. In vitro skin permeation experiments
The method of in vitro skin permeation experiment was the same as described in
previous chapter.
3.2.5. Scanning electron microscopic observation
The method of scanning electron microscopic observation was the same as
described in previous chapter.
3.2.6. Measurement of skin redness and cutaneous blood flow
The skin redness and cutaneous blood flow were determined on a scale of the
indeces of skin irritation [88]. The study was performed at ambient temperature (24
± 1 °C). Three circular areas with a diameter of 1 cm were marked on the abdomen
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of each hairless rat. The skin color was measured using a Minolta CR-400
chromameter (Konicaminolta Sensing Inc., Osaka, Japan). The chromameter was
rectified before measuring the skin using the color standard (Perimed AB, Jarfalla,
Sweden). The detection head of the chromameter was placed gently onto the skin to
measure the skin color, and the value of a* (AU) was recorded. Subcutaneous blood
flow was imaged before application of the MN-electrode arrays with a laser Doppler
perfusion imager (LDPI; Perimed AB) and PeriScan PIM 3 (Perimed AB) to avoid the
vein, which would interfere with blood flow measurements before application of the
MN-electrode arrays. The distance between the LDPI measuring head and the skin
surface was set at 20 cm and the images were analyzed by calculating the mean blood
flow over the marked area within the abdomen skin, corresponding to the size of the
mold of the MN array. Blood flow was expressed as perfusion units (PU). Skin
redness and cutaneous blood flow were determined after the following treatments: (i)
non-pretreated skin as a negative control, (ii) MN alone, (iii) IN-SKIN EP (50 V, 100
ms, 10 pulses), (iv) ON-SKIN EP (50 V, 100 ms, 10 pulses) and (v) IN-SKIN EP
(100 V, 100 ms, 10 pulses).
The skin redness and cutaneous blood flow were measured 0, 15, 30, 45, 60, 90
and 120 min after application. Before applying the MN arrays or IN-SKIN EP,
baseline values were recorded for the cutaneous blood flow and skin color.
3.2.7 In vivo experiment
The hairless rats were anesthetized by peritoneal injection of urethane (1.0 g/kg)
and the hair on the abdomen was carefully shaved using an electric clipper. Their
body temperature was maintained at 36.5 ± 0.5 °C throughout the experiments with a
piece of electric carpet. An area of skin on the abdomen was manually punctured
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using the MN-electrode array with vertical pressure of 3.53 N/cm2 for 10 sec in the
IN-SKIN EP application with the device B. Then, a donor cell was immobilized
onto the punctured area by adhesive compound. The test FD-4 solution (1.0 mg/mL,
1.0 mL) was added to the donor cell. The preparation of blood samples was the
same as in 1.2.5., and plasma samples were measured by using the method in 1.2.8.
3.2.8. Statistical analysis
Statistical analysis was performed using Student’s t-test and ANOVA. A p
value less than 0.05 was considered significant.
3.3. Results and discussion
3.3.1. Effect of IN-SKIN EP pretreatment on the skin permeation of FD-4
Figure 18a and b show the time courses of the cumulative amount of FD-4 that
permeated skin pretreated with ON-SKIN EP (50 V, 100 ms, 10 pulses) and IN-SKIN
Fig. 18. Time courses of the cumulative amount of FD-4 that permeated through skin
pretreated by ON-SKIN EP (a) and IN-SKIN EP (b) with three kinds of devices.
Symbols: ◆, device A; ■device B; ▲, device C. (EP condition: 50 V, 100 ms, 10
pulses)
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EP (50 V, 100 ms, 10 pulses), respectively. While the cumulative amount of FD-4
permeated through the skin was 0.03 ± 0.002 µg/cm2 over 8h for the non-pretreatment
group [89], the corresponding values for the ON-SKIN EP using devices A, B and C
were approximately 6-fold (0.17 ± 0.06 µg/cm2), 18-fold (0.54 ± 0.09 µg/cm2) and
4-fold (0.13 ± 0.02 µg/cm2) higher, respectively, than the non-pretreatment group.
Device B showed the highest permeation-enhancing effect.
On the other hand, the permeation-enhancing effect over 8 h by IN-SKIN EP
using device A, B and C was nearly18-fold (0.53 ± 0.18 µg/cm2), 59-fold (1.77 ± 0.65
µg/cm2) and 15-fold (0.44 ± 0.04 µg/cm2), respectively, in comparison with the
non-pretreatment group. Device B also showed the highest effect by the IN-SKIN
EP. The order of the penetration-enhancing effect was device B >> device A >
device C both for the ON-SKIN EP and IN-SKIN EP applications. In addition, it is
clear that the IN-SKIN EP had a much higher penetration-enhancing effect than the
Fig
and
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ede. 19. SEM microphotograph of the skin surface after application of IN-SKIN EP
ON-SKIN EP with different electrode (EP condition: 50 V, 100 ms, 10 pulses).
ON-SKIN EP (anode), (b) ON-SKIN EP (cathode), (c) IN-SKIN EP (anode), (d)
SKIN EP (cathode), and (e) Enlarged drawing of Fig. 3d, the ring shows38
matous swelling around the pore.
39
ON-SKIN EP when applying the same voltage with the same pulse width.
3.3.2. Scanning electron micrographic observation
Figure 19 shows SEM photographs of the effect of ON-SKIN EP and IN-SKIN
EP by a single needle on the skin surface. All of the EP treatments were performed
using a single pair of electrodes under conditions of 50 V, 100 ms and 10 pulses,
which were the same conditions as in the skin permeation experiment. The
ON-SKIN EP showed moderate change of the skin surface morphology (Fig. 19a and
b). On the other hand, the IN-SKIN EP produces transport channels across the
primary barrier, the stratum corneum, for macromolecular drug entry into viable
tissues (Fig. 19c and d). The pore channels produced by the IN-SKIN EP which
functioned as new and effective pathways of chemical compounds through skin, and
such channels could be utilized for the skin permeation pathway for high molecular
compounds as well as low molecular compounds. The diameter of the produced
transport channels in the skin was measured, and their average size was used as an
index of the channel size. The average diameter of the marks produced by the
anodes and cathodes for the ON-SKIN EP was calculated to be 186 μm (Fig. 19a) and
62 μm (Fig. 19b), respectively. In the case of IN-SKIN EP, the average diameter of
the channel produced by the anode was 199 μm (Fig. 19c), with 66 μm for the cathode
(Fig. 19d). The size of pores created by a single pair of electrodes corresponded to
that by MN-electrodes array devices (device A, B and C) (data not shown).
According to these SEM observations, the anodes were found to contribute more to
the drug delivery pathway than the cathodes. These data above were closely related
to device B showing the highest permeation-enhancing effect, and device C showing
the lowest effect among three devices (Fig. 18).
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Interestingly, edema was found around the pore, with a diameter of about 1 mm,
as shown in Fig. 19e under a lower multiplying factor, in skin pretreated by the
cathode. On the other hand, no such edema could be found in the skin after
pretreatment by the anode. Water flux (electrosmosis) from the anode to cathode
may be the reason for the edema under the cathode.
3.3.3. Influence of IN-SKIN EP on skin redness and blood flow
Because heat-generated wave of EP propagates outward from the applied site
[90], EP pretreatment might affect the deeper tissues under the skin surface, even
cutaneous capillary vessels. Hence, the changes in skin redness and blood flow were
further evaluated in the present study. The irritation index was measured both with a
chromameter and an LDPI. Both apparatuses can measure the erythema in skin.
The chromameter evaluates skin surface redness, while the LDPI measures blood flow
in much deeper skin layers. The exact penetration depth of the laser depends on the
extent of pigmentation, but the obtained image reflects cutaneous blood flow with a
depth less than 1 mm [91]. The redness and blood flow after IN-SKIN EP treatment
were evaluated under the same conditions as in the skin permeation experiment (50 V,
100 ms, 10 pulses). MN treatment and ON-SKIN EP treatment (50 V, 100 ms, 10
pulses) were also evaluated for comparison.
Safety evaluation was conducted using device B and device C, which showed the
highest and lowest skin permeation-enhancing effects, respectively. Figure 20 shows
the change in redness (Δa) for devices B and C. The shadow part in Fig. 20
represents the variation in redness for non-pretreatment (control). In the present
study, the variation of control was determined as an acceptable range for all
pretreatments. Skin redness did not change markedly: IN-SKIN EP treatment
resulted in the maximum Δa values 15 min after application, 0.36 ± 0.09 absorption
units (AU) for device B and 0.22 ± 0.14 AU for device C; however, these maximum
values returned to the control value within 45 min. MN and ON-SKIN EP did not
show more irritation than the non-treatment group.
The change in blood flow showed a similar tendency to that in skin redness
Fig. 2
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(Fig. 21). The maximal blood flow was observed immediately after IN-SKIN EP
treatment. The vasodilation response caused by the inflammatory reaction in the
dermis must be faster than the redness response on the skin surface. The maximum
values were 29 ± 3 PU and 26 ± 6 PU for device B and C, respectively, and returned
to the acceptable range within 15 min.
No significant difference was observed in skin redness and cutaneous blood flow
between devices B and C (P< 0.01). These data suggest that the EP condition (50 V,
100 ms, 10 pulses) in the present in vitro study could be considered safe.
Next, the effect of EP voltage on redness and blood flow was investigated. As
shown in Fig. 22a and b, EP treatment with 100 V resulted in significantly higher
redness (1.61 ± 0.41 AU) and greater blood flow (97 ± 5 PU), respectively, than
non-pretreatment skin, for device B after application (P<0.01).
The blood flow returned to the acceptable range within 45 min and redness
remained until 90 min, which indicated a longer irritation period than EP treatment
with 50 V.
Fig. 22. The change in redness (a) and blood flow (b) at different time points after
pretreatment of IN-SKIN EP (100 V, 100 ms, 10 pulses) with device B. Symbols:
◆, non-pretreatment; ▲, IN-SKIN EP (100 V, 100 ms, 10 pulses).
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Subcutaneous blood flow was also monitored by an LDPI. Figure 23b shows
representative pictures and perfusion images of skin after IN-SKIN EP application
(100 V, 100 ms, 10 pulses) with device B. These images show the same skin area
before and after treatment at different time points. Figure 23a shows those for
non-pretreatment. The applied area in the perfusion image turned red and then
returned to normal within 45 min after IN-SKIN EP application (Fig. 23b) compared
to non-pretreatment (Fig. 23a). These results might indicate that the increase of
voltage increases the skin irritation by the IN-SKIN EP.
In vivo experiment was performed to evaluate the effect of the IN-SKIN EP
means on the skin permeation of drugs. Plasma concentration-time profiles of
FD-4 after i.c. injection with a 33 G needle and IN-SKIN EP pretreatment were
Fig. 23. Laser doppler perfusion images and pictures of hairless rat abdomen skin.
The images show the change in blood flow at different time points. (a) skin
without pretreatment, (b) the skin after the pretreatment of IN-SKIN EP (100 V, 100
ms, 10 pulses). The time points: (1) before, (2) 0 min (just after application), (3) 15
min, (4) 30 min, (5) 45 min, (6) 60 min, (7) 90 min and (8) 120 min.
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Conclusion
The following conclusion can be obtained from the present results:
(1) 33 G-needles could provide less invasive injection and more steady plasma drug
level. I.c. injection showed a higher absorption than s.c. and i.m. injection for a
model macromolecule, FD-4, so the feasibility of the transdermal delivery of
macromolecules was expected.
(2) IN-SKIN EP can effectively deliver high molecular and hydrophilic drugs, which
was probably due to a great synergistic effect by MN and ON-SKIN EP. In
particular, higher permeation of FD-4 was achieved when applying higher voltage and
longer pulse width of EP.
(3) The anode and cathode positions and the electric field strength in the stratum
corneum were the important determinants for the EP effect. The device with one
central cathode and 8 surrounding anodes showed the most significant
permeation-enhancing effect of FD-4 through skin. Besides, the IN-SKIN EP did
not show any severe irritation on skin.
The presently proposed IN-SKIN EP is able to overcome the stratum corneum
barrier with only minimal irritation, which opens the opportunity for dermal and
transdermal delivery of high molecular weight/high hydrophilic drugs together for
vaccine delivery.
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